Pharvaris N.V.

NASDAQ:PHVS

Biotechnology

Healthcare
$31.55 -1.93%

-$0.64 today

Market cap
$2.21B
Beta
-2.33
P/E (TTM)
-11.0
EPS (TTM)
-$2.59
52W Low $16.72High $34.41

Volume 0.39M

Average 0.31M

PHVS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Pharvaris N.V.NASDAQ: PHVS

Weighted Avg Shares · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares of 70.33M shares rose 13.0% year over year, behind the +16.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.3% from the prior quarter. Over 3 fiscal years it compounded at +20.8% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +13.0% toward the trailing-twelve-month pace of +16.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
70.33M+3.3% QoQ
Last fiscal yearDec 2025
59.16M+9.5% YoY
LTMSep 2026
65.72M+16.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.0%——
1 year+9.5%——
3-year CAGR+20.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
59.16M EUR
Year-over-year change
+9.5%
4-year CAGR
+18.1%

Weighted Avg Shares vs competitors

How PHVS compares with its peers on the latest reported figures

  • PHVS's LTM Sep 2026 weighted avg shares of 65.72M shares is the 6th highest of the 7 companies compared; the peer median is 80.21M shares.
  • Its year-over-year change of +16.6% is the highest of 7, against a peer median of +3.3%.
  • Over three fiscal years its annual growth of +20.8% compares with a peer median of +8.0%.
PHVS Competitors Peer median
Weighted Avg Shares for PHVS and competitors
Company Period LTM YoY 3-year CAGR
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026229.47M +10.2%+4.1%
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026192.71M +0.7%+1.2%
TVTXTravere Therapeutics, Inc.LTM Sep 202692.57M +5.9%+11.8%
VERAVera Therapeutics, Inc.LTM Jun 202667.85M +14.4%+34.2%
PHARPharming Group N.V.LTM Mar 202667.56M -5.0%-4.8%
PHVSPharvaris N.V.LTM Sep 202665.72M +16.6%+20.8%
RLYBRallybio CorporationLTM Mar 20265.55M -0.3%+12.3%
Peer median (excluding PHVS) 80.21M+3.3%+8.0%

Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development35.79M57.38M65.58M98.56M124.48M
Selling, General & Admin18.35M29.34M31.34M47.12M45.34M
Operating Expenses54.14M86.71M96.91M145.69M169.82M
Depreciation & Amortization77.37K152.94K257.55K269.56K418.35K
EBITDA(42.31M)(86.56M)(99.57M)(145.42M)(173.29M)
EBITDA Margin—————
Operating Income(54.14M)(86.71M)(96.91M)(145.69M)(169.82M)
Operating Margin—————
Interest Income2681605.47M0
Interest Expense278.18K16.11K000
Other Income / Expenses11.48M11.06M(2.91M)13.29M(3.89M)
Income Before Tax(42.66M)(75.65M)(99.83M)(132.4M)(173.71M)
Pre-Tax Margin—————
Income Tax Expense70.12K679.09K1.05M1.83M1.99M
Net Income(42.73M)(76.33M)(100.88M)(134.22M)(175.7M)
Net Margin—————
EPS (Basic)(1.41)(2.27)(2.63)(2.48)(2.97)
EPS (Diluted)(1.41)(2.27)(2.63)(2.48)(2.97)
Weighted Avg Shares30.41M33.59M38.39M54.02M59.16M
Weighted Avg Shares (Diluted)30.41M33.59M38.39M54.02M59.16M

Pharvaris N.V.

NASDAQ:PHVS

Intrinsic Alpha fair value

Locked

Current Price

$31.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.